Statens Serum Institut — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Statens Serum Institut appears in 21 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials21

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

21 shown

HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent DiseaseNCT01141205 · lead sponsor · 2009-08-01

Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-InfectionNCT00856154 · lead sponsor · 2007-01-01

LiPO Teen (the Lifestyle in Pregnancy and Offspring TeenagersNCT05774652 · collaborator · 2023-10-26

Holbæk Obesity Treatment (HOT) Versus Conventional Obesity Treatment (COT) in Children With Overweight or Obesity.NCT05038683 · collaborator · 2022-10-26

Skeletal Maturation and Endocrine Health in Young AdultsNCT06509776 · collaborator · 2024-11-11

ENROLLING_BY_INVITATION

Twelve-year Follow-up on the Treatment of Obese Pregnant Women (TOP) StudyNCT05446220 · collaborator · 2023-01-05

Study to Evaluate H56:IC31 in Preventing Rate of TB RecurrenceNCT03512249 · collaborator · 2019-01-31

Effect of Probiotics (Vivomixx®) on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their NewbornNCT02508844 · collaborator · 2015-04-01

A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TBNCT02375698 · collaborator · 2014-11-21

A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)NCT01865487 · collaborator · 2013-08-01

Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed InfantsNCT01861730 · collaborator · 2013-07-01

Safety and Immunogenicity Study of AERAS-456 Vaccine for TuberculosisNCT01967134 · collaborator · 2011-11-01

Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety StudyNCT01006941 · collaborator · 2010-05-01

Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infectionNCT01009762 · collaborator · 2009-09-01

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)NCT02109874 · collaborator · 2008-12-01

The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 DiabetesNCT00699426 · collaborator · 2008-06-01

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in AdultsNCT02074956 · collaborator · 2008-05-01

A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis InfectionNCT02066428 · collaborator · 2007-11-01

Adipose Expression of Leptin, Adiponectin and IL-6 and Plasma Levels of Adipocytokines in Women With and Without Polycystic Ovary Syndrome (PCOS)NCT01088061 · collaborator · 2004-01-01

Bloodstream Infections in Patients With Rheumatoid ArthritisNCT03908086 · collaborator · 1996-12-31

Adipocytokines and Polycystic Ovary Syndrome (PCOS)NCT00975832 · collaborator

Sponsor roles

collaborator19

lead sponsor2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.